Disc Medicine (IRON) Non-Current Deffered Revenue (2020)
Disc Medicine (IRON) reported Non-Current Deffered Revenue of $4.2 million for Q4 2020, little changed on a QoQ basis from $4.2 million in Q3 2020.
Disc Medicine (IRON) has 1 years of Non-Current Deffered Revenue data on file, last reported at $4.2 million in Q4 2020.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $4.2 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $4.2 million (changed N/A YoY) and the FY2020 annual result came in at $4.2 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was little changed at $4.2 million in Q4 2020 per IRON's latest filing, from $4.2 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $4.2 million in Q3 2020 and bottomed at $4.2 million in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 4.23 Mn |
| Sep 30, 2020 | 4.23 Mn |